Pentac

Quick links to important sections

Pentac

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pentac

Quick Facts

Property Description
Active Ingredient Ranitidine Hydrochloride
Primary Form Tablet (Oral)
Pharmacological Class Histamine H2 receptor antagonist (H2 blocker)
General Purpose To reduce stomach acid secretion
Origin Synthetic Compound

What Type of Medicine is Pentac?

Pentac is the trade name for a medication whose primary active component is Ranitidine, a substance classified as a gastrointestinal agent. Ranitidine is specifically known as a Histamine H2 receptor antagonist, or H2 blocker, a classification based on its pharmacological properties. This means the drug's essential function is to influence the chemical signaling pathway that drives acid secretion. As a synthetic compound, Ranitidine is chemically manufactured. This medication is clinically recognized for its efficacy in controlling gastric acid levels, offering a targeted solution compared to general antacids.

What is Pentac Made Of and What Forms Does it Come In?

The core active substance in standard Pentac is Ranitidine Hydrochloride. It is typically provided for the oral route of administration, most commonly as a tablet, although an injectable solution is available for specific clinical needs. Differentiation occurs with formulations like Pentac D, which is a combination product pairing the acid-reducing Ranitidine with a second distinct agent, such as a prokinetic. This specialized combination addresses both acid production and the movement of the digestive tract, positioning Pentac as a versatile option.

What is the General Purpose of Pentac?

The fundamental purpose of Pentac is to promote digestive comfort by significantly reducing the acidity of stomach contents. Ranitidine acts by reducing gastric acid secretion. This therapeutic action helps manage symptoms like persistent, recurring indigestion. Furthermore, clinical experience with this drug class indicates that this reduction in acid is key to helping damaged tissue in the esophagus and stomach heal. The ultimate benefit of this medicine is to protect the sensitive lining of the digestive tract from acidic irritation, thereby easing related discomfort.

Regulatory References

  1. H₂ blocker

What side effects are possible with Pentac?

Possible Side Effects and Safety Information

The safety profile of Pentac (Ranitidine) is structured according to official regulatory classification, detailing adverse reactions by the affected body system and frequency of occurrence. Safety documentation distinguishes between common and rare reactions.

Commonly documented effects include disturbances within the Nervous System, such as headache, which is frequently reported. Other adverse reactions involve the Gastrointestinal System, listing effects such as diarrhea, constipation, nausea, and abdominal discomfort.

Classification of Adverse Reactions
Rare reactions (1/10,000 to leq 1/1,000) include hypersensitivity reactions, such as fever or rash.
Very rare reactions (leq 1/10,000) involve serious effects like blood count changes (e.g., pancytopenia), specific cardiac arrhythmias (e.g., bradycardia), hepatitis (liver inflammation), and reversible mental confusion.

Serious adverse reactions documented in regulatory sources primarily involve hepatotoxicity and potential severe blood count changes. Safety notes specify that a therapeutic response to the medicine does not exclude the presence of a gastric malignancy (stomach cancer), and this must be considered. In severely ill and older adults, there is an increased reporting rate of reversible central nervous system effects, such as mental confusion.

Furthermore, all Ranitidine products are subject to a major regulatory constraint related to the risk of N-Nitrosodimethylamine (NDMA) contamination, a probable human carcinogen, which led to the suspension or withdrawal of the medicine by major global health authorities. This risk is associated with the long-term stability of the drug, where NDMA levels may increase over time.

Overdose and Emergency Response

Overdose Profile and Emergency Action

Officially documented signs of over-ingestion of Pentac (Ranitidine) involve both the Central Nervous System (CNS) and the cardiovascular system. Manifestations may include a lack of coordination, fainting, or feeling light-headed. Other recognized signs include nausea, vomiting, and diarrhea. CNS effects can escalate to confusion, agitation, hallucinations, and slurred speech. Cardiovascular signs observed in overdose contexts include abnormal heartbeat (arrhythmia) and low blood pressure.

When to Seek Help

Regulatory authorities mandate that in case of a known or suspected over-ingestion, individuals must get medical help or contact a Poison Control Center right away. Immediate emergency services are required if the affected person has difficulty breathing, has suffered a seizure, has collapsed, or cannot be awakened. These actions are crucial for initiating professional care.

Management and High-Risk Populations

Treatment for overdose is officially defined as symptomatic and supportive. This approach involves continuous monitoring of the patient's vital signs and cardiac function, often via an ECG (heart tracing). The official prescribing information notes a specific risk consideration for certain populations: the drug's total clearance is reduced in patients with significant renal function impairment and in the elderly population. This physiological change may increase the risk of drug accumulation and heightened adverse effects in an overdose scenario.

Therapeutic Uses of Pentac

What Pentac Treats: Main Uses and Benefits

Pentac is commonly used in therapeutic domains relevant to managing conditions characterized by heightened symptoms related to irritative states. Its therapeutic relevance spans several key gastrointestinal domains.

The medication is applied to address conditions involving inflammatory or irritative processes, including duodenal and benign gastric ulcers, Gastroesophageal Reflux Disease (GERD), and pathological hypersecretory conditions. It is also considered relevant when supportive symptom management is appropriate in specific clinical settings, such as to mitigate the risk of stress ulcers in high-risk patients.

It is commonly used to help with persistent heartburn, upper abdominal discomfort, and symptoms related to active ulcerations. This action supports the patient during difficult episodes by easing symptoms that interfere with daily functioning. This action contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Acid-Related Discomfort
Primary Symptom Focus Burning pain and discomfort from acid reflux and ulceration.
Key Patient Benefit Supports easing the overall symptom load for improved day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Pentac?

The official regulatory profile for Pentac (Ranitidine) defines patient eligibility based on specific contraindications and required precautions, as documented by national health authorities.

Eligibility Restrictions

Classification Population/Condition
Contraindicated Patients with known hypersensitivity to ranitidine or any ingredient; Individuals with a history of acute porphyria.
Not Recommended Children under 12 for Over-The-Counter (OTC) use.
Use Not Established Infants under one month of age (Neonates).

Conditional Use Requirements

Use is restricted in several populations due to safety considerations or altered drug clearance:

  • Impaired Renal Function: Dosage must be reduced in patients with a creatinine clearance less than 50 mL/min.
  • Pregnancy and Lactation: Use is recommended only if clearly essential, as the drug is known to be excreted into human milk.
  • Organ Screening: For patients diagnosed with a gastric ulcer, the possibility of underlying gastric malignancy must be excluded prior to starting therapy.
  • Older Adults: Caution is advised, and regular supervision is recommended when these patients are taking NSAIDs concurrently.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for Pentac (pentosan polysulfate sodium) as described in authoritative governmental regulatory documents.


Pharmacodynamic Interaction Profile

The primary interaction concern documented in labeling is a significant increase in the risk of bleeding and hemorrhage. This risk is heightened when Pentac, which has weak anticoagulant properties, is taken concurrently with other medicinal products that affect blood coagulation or platelet function.

Category of Interacting Product Examples Official Interaction Statement
Anticoagulants Warfarin, Heparin Increased risk of hemorrhage
Antiplatelet Agents High-dose Aspirin, NSAIDs Increased risk of hemorrhage
Thrombolytics t-PA, Streptokinase Increased risk of hemorrhage

Pharmacokinetic and Administration Constraints

Official labeling does not define clinically significant interactions based on specific cytochrome P450 enzyme inhibition or induction, nor on major drug transporter systems. For instance, co-administration with warfarin does not affect the pharmacokinetics of warfarin enantiomers.

An administration constraint is documented regarding food: the medication must be taken with water at least one hour before or two hours after meals.


Population and Condition Constraints

Caution is advised for patients with hepatic insufficiency because the drug is metabolized in the liver and spleen by desulfation, and the effect of liver impairment on drug exposure is not fully documented. Patients with pre-existing coagulopathy or other conditions that increase the risk of bleeding should be carefully evaluated before initiating therapy.

Mechanism of Action

Blocking the Signal for Gastric Acid Production

The primary mechanism involves Ranitidine acting as a competitive antagonist at the Histamine H2 Receptors ( H2 R), which are located on the basolateral membrane of the gastric parietal cells. By occupying these receptors, Ranitidine effectively interrupts the intracellular signaling cascade, specifically the cAMP pathway, that typically drives acid secretion. This molecular blockade leads to a reduction in the volume and H^+ concentration of gastric secretions.

Enhancing Upper Gastrointestinal Clearance (Combination Products)

In combination products (e.g., Pentac D), a secondary mechanism influences gastrointestinal motility. This involves modulating neurotransmitter signaling, typically by antagonizing Dopamine D2 Receptors and/or inhibiting the Acetylcholinesterase enzyme within the enteric nervous system. This action enhances the excitatory effects of acetylcholine, which strengthens smooth muscle tone and accelerates propulsive peristalsis.

Mechanistic Constraints

The H2 R blockade is based on competitive binding, meaning the mechanism's effect can be modulated by the local concentration of stimulating agents. The two mechanistic domains—chemical suppression and physical clearance—operate concurrently.

Dosage and Administration Information

How Pentac is Used: Administration Guidelines

Pentac (ranitidine) is administered according to standardized regimens. The approved routes of administration are Oral (most common), Intravenous (IV), and Intramuscular (IM), with forms available as tablets (150 mg and 300 mg), oral solution, and injection.


Standard Dosing and Frequency

Feature Guideline Details
Oral Dosing (Adult) 150 mg twice daily, or 300 mg once daily. For highly acid-secreting conditions, doses may be initiated at 150 mg three times daily, with a maximum dose of up to 6 g/day in extreme cases.
Parenteral Dosing (IV/IM) 50 mg every 6 to 8 hours. Continuous IV infusion is administered at a rate of 6.25 mg/hour.
Treatment Duration Acute treatment courses typically last 4 to 8 weeks; long-term, maintenance therapy is prescribed at a reduced dose (e.g., 150 mg at bedtime).

Procedural and Population Rules

Context-of-Use Instructions: Oral tablets may be taken with or without food; the once-daily dose is typically scheduled for bedtime. Specific formulations, such as effervescent tablets or granules, must be completely dissolved in a full glass of water prior to ingestion. The injection solution requires dilution and must be administered slowly.

Dose Adjustment: A dose reduction is indicated for patients with impaired renal function (creatinine clearance less than 50 mL/min), with a recommended oral dose of 150 mg every 24 hours. Pediatric dosing is weight-based, typically 2 to 4 mg/kg twice daily.

Missed Dose Protocol: If a dose is missed, it should be taken as soon as the lapse is remembered; however, if the next scheduled dose is imminent, the missed dose is skipped, and the regular schedule resumes.

These instructions define the precise route, dosage, frequency, and preparation steps necessary for the administration of the medication.

Recent Clinical Evidence

Research evidence / Overview of Studies for Pentac (Ranitidine)

According to the official research base, the available information about Ranitidine, the active substance in Pentac, comes from official sources like regulatory bodies and peer-reviewed scientific literature. Research has explored how the active substance, Ranitidine, has been evaluated in various conditions by observing patterns in patient groups under controlled conditions.


Evidence for Use in Healing Active Ulcers (Duodenal and Gastric)

Research into this area has primarily involved short-term Randomized Controlled Trials (RCTs) and systematic reviews. Researchers focused on adult populations who had endoscopically confirmed ulcers. The main outcomes related to physical discomfort that were studied included endoscopic ulcer healing rates (which measure the observed change in tissue state over a defined time) and patient-reported outcomes describing perceived discomfort.

The studies describe patterns of measured symptom change in the observed populations during periods typically lasting from 4 to 8 weeks. These short follow-up durations mean that while the acute phase was well-studied, data are still limited regarding the sustained stability of the tissue condition over much longer periods. Results apply only to the populations studied.


Research on Managing Gastroesophageal Reflux Disease (GERD)

Studies monitored conditions characterized by fluctuating or episodic manifestations, such as heartburn and reflux symptoms. The evidence base includes RCTs that explored the observed changes in heartburn symptoms and the endoscopic status of tissue damage in the esophagus.

Findings help contextualize how patients reported their experience, with research highlighting changes measured in symptoms over treatment periods, typically 2 to 12 weeks. Data for certain groups, such as the full spectrum of outcomes linked to inflammatory or irritative states in patients with milder, non-erosive GERD, remain insufficient. The long-term changes on daily functioning are not fully established based on this specific body of work.


Studies on Long-Term Use and Maintenance

Trials studying ulcer recurrence were conducted using long-term randomized maintenance trials that explored how symptoms changed over time in the observed populations. Studies documented the frequency of ulcer recurrence over periods that often spanned one year or more. Most of this available evidence is derived from trials conducted several decades ago. While this evidence contributes to the broader evidence landscape, long-term effects are not fully established in contemporary patient cohorts.

Key Studies & References

  1. Suspension of medicinal products containing ranitidine in the European Union (Regulatory document on suspension and alternatives)
  2. Ranitidine use in pediatrics: current evidence-based review and recommendations (Review on pediatric use, including GERD and prophylaxis)

Frequently Asked Questions (FAQ)

Common questions about Pentac (FAQ)

Q: How quickly can someone expect Pentac to start reducing stomach acid?

Regulatory documents indicate that symptomatic relief of conditions like GERD is commonly experienced by patients within 24 hours of starting the medication. This time frame is based on typical starting regimens observed in clinical studies.

Q: What are the official, regulated medical uses for Pentac?

The official, regulated uses include the short-term treatment of active ulcers in the stomach and small intestine, as well as the long-term maintenance therapy for healed ulcers. It is also used for the treatment of GERD (acid reflux) and certain conditions that cause excessive acid production.

Q: Can Pentac be used for conditions other than acid reflux or ulcers?

Yes, the official indications extend beyond just treating common acid reflux symptoms and ulcers. The medication is also indicated for use in managing pathological hypersecretory conditions, such as Zollinger-Ellison syndrome and systemic mastocytosis.

Q: Does the effect of Pentac last for a full 24 hours?

According to official pharmacokinetic studies, a single dose of the medication results in drug concentrations high enough to inhibit a significant amount of stimulated stomach acid secretion for approximately 12 hours. This duration is an average finding observed in clinical research.

Q: Is Pentac used for the prevention of ulcers, or only for treating existing ones?

Yes, the medicine is used in both ways. Regulatory labeling describes its use for the short-term treatment of active ulcers as well as for long-term maintenance therapy. This maintenance use is prescribed at a reduced dose after an ulcer has healed to help prevent their recurrence.

Q: Are there any side effects that could indicate a more serious health issue with Pentac?

The official safety profile documents very rare, but serious, effects such as changes in blood cell counts, signs of liver inflammation (hepatitis), and specific heart rhythm disturbances like bradycardia (a slow heart rate).

Q: Can taking Pentac cause a feeling of drowsiness or tiredness?

Official safety documents list rare side effects affecting the nervous system. These documented effects include dizziness and somnolence, which is a medical term for drowsiness.

Q: Are the common side effects of Pentac generally temporary?

Studies have examined the duration of common side effects. Clinical data indicates that some common gastrointestinal side effects, such as abdominal pain, constipation, and nausea, have generally tended to improve with continued use of the medication.

Q: Does Pentac interact with any common anti-fungal medicines?

Official information indicates that this medicine can reduce stomach acid, which may change how well certain other drugs are absorbed into the body. This is known to include some types of antifungal medicines, such as ketoconazole and itraconazole.

Q: Is Pentac considered safe for use in older adult patients?

Official labeling notes that the drug’s processing time in the body may be prolonged in older adults due to reduced drug clearance. This population may also have an increased reporting rate of reversible central nervous system side effects, such as mental confusion.

Q: Is it necessary to avoid alcohol completely while taking Pentac?

The drug is not known to have a clinically significant interaction with alcohol that changes how the medicine works in the body. However, official information for patients treating ulcers notes that alcohol can increase irritation in the stomach lining and potentially slow the healing process of the ulcer.

Q: Do certain foods or drinks need to be avoided when taking Pentac for maximum effect?

Regulatory information notes that food does not significantly impair the absorption of the medicine, and official guidelines state the medication is administered without regard to meals. However, for the purpose of heartburn prevention, it is sometimes taken about 30 minutes before consuming items known to trigger symptoms.

Q: What are the general research themes published about the long-term use of Pentac?

Studies have examined the long-term use of this medicine for preventing the recurrence of ulcers. These placebo-controlled maintenance trials have typically been carried out for periods lasting up to one year. In shorter-term studies focused on healing active ulcers, safety has generally not been assessed beyond an 8-week period.

Q: Does Pentac require a prescription, or is it available over the counter in some places?

The medication is available in both prescription (Rx) and over-the-counter (OTC) forms, depending on the specific strength and formulation. For example, lower doses may be available without a prescription for certain uses.

Q: How is Pentac used in the management of Zollinger-Ellison syndrome?

According to official indications, this medication is used for treating conditions that cause pathological hypersecretion, which means the stomach produces excessive amounts of acid. This includes conditions such as Zollinger-Ellison syndrome and systemic mastocytosis.

Q: What precautions are listed for patients who have been diagnosed with a heart condition?

The official safety documentation includes rare adverse reactions that affect the heart, such as changes in heart rhythm called cardiac arrhythmias and bradycardia, which is a slow heart rate.

Q: Is there information on Pentac's potential effect on sexual desire or function?

Official safety documentation has included rare or very rare reports of effects on sexual function. These reported effects include the possibility of loss of libido (sexual desire) and reversible impotence.

Q: What are the common misunderstandings about how Pentac should be stored?

Official guidance for the reformulated product details the requirements for storage. These requirements state that the tablets must be kept in the original bottle with the desiccant packet to protect them from moisture, and that they must be discarded 90 days after the bottle is first opened.

Q: Is there any research evidence on Pentac's use in children?

Regulatory bodies have established that the medication is suitable for use in children and adolescents aged 1 month to 16 years. However, official information notes that there is insufficient data for creating dosing recommendations for neonates, who are infants less than one month old.

Q: What are the indications that Pentac might not be working as intended?

Official warnings advise caution if the condition does not begin to improve or if symptoms worsen while taking the medication. Cautions are also advised if symptoms of more serious underlying conditions occur, such as unexplained weight loss.

Q: Do official documents mention any effects of Pentac on vision or alertness?

Official documentation lists reversible blurred vision as a rare side effect affecting the eyes. General nervous system side effects can also occur, including dizziness and a feeling of sleepiness.

Q: Is there a difference in strength or effect between the 150 mg and 300 mg versions of Pentac?

Official studies have compared different dosing regimens and found that taking a lower strength twice daily and a higher strength once at bedtime resulted in similar rates of ulcer healing. The higher strength once-daily option is sometimes offered for dosing convenience.

Q: What are the known drug-condition interactions for Pentac?

Official product information lists conditions that affect how the medicine is used. For instance, patients with impaired renal (kidney) function require a dosage adjustment. The drug is also contraindicated for individuals with a history of acute porphyria, which is a rare metabolic disorder.

Q: Does taking Pentac impact any laboratory test results?

Yes, regulatory information notes that this medication may interfere with certain laboratory results. Specifically, it can cause false-positive results in particular urine protein tests (like those using Multistix) and may also affect the results of certain liver function tests.

Q: Is it true that Pentac can be used to treat symptoms caused by non-steroidal anti-inflammatory drugs (NSAIDs)?

Official indications for this medicine include its use to treat or prevent stomach ulcers. These ulcers are sometimes caused by the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen.

Q: Are there any warnings regarding potential interactions between Pentac and herbal supplements?

Official information advises caution regarding certain herbal supplements. Warnings are associated with using supplements like ginkgo biloba (due to a potential bleeding risk) and St. John’s wort with this medication.

Q: Can Pentac be taken at the same time as other acidity-treating medicines like antacids?

Official pharmacokinetic information indicates that the absorption of this drug is generally not significantly affected by taking it with antacids.

Q: Does Pentac reduce the absorption of any important vitamins or minerals?

Because this medication reduces stomach acid, it may be associated with decreased absorption of certain nutrients from food. Regulatory safety reviews have noted this potential effect, most notably with Vitamin B12.

How should Pentac be stored and disposed of?

The substance commonly referred to as Pentac is Polychlorinated Biphenyls (PCBs), which are regulated as industrial chemicals and hazardous waste, not as a modern pharmaceutical drug. Therefore, standard drug storage and disposal guidelines are not applicable.

️ Important Regulatory Notice: Pentac (PCBs) Disposal

Storage & Disposal Scope Official Regulatory Requirements (US EPA)
Handling Equipment containing PCBs must be clearly labeled with a PCB Caution Label and stored in designated areas.
Storage Time Storage of PCB waste prior to disposal is time-limited, generally to one year from the date the material was designated as waste.
Disposal Classification PCBs are classified as Controlled Chemical/Hazardous Waste under the Toxic Substances Control Act (TSCA).
Disposal PCB waste must be disposed of in a manner that ensures destruction or permanent underground storage, following the strict regulations outlined in 40 CFR Part 761. General disposal, such as open burning or disposal into waterways, is prohibited.

Due to its classification as a hazardous chemical waste, professional, regulated disposal is mandatory. Do not dispose of this substance with household trash or down the sink or toilet. Proper disposal involves transporting the material to an approved waste management facility that complies with federal environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pentac found in:

A-Z Index: